Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients
with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to
grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with
metastatic kidney cancer.